Fresh off $45-million Series B round, the CRISPR diagnostics developer expands beyond disease detection into gene editing partnerships and next-gen therapeutics
Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—toward offerings that apply the company’s platform to gene editing and next generation therapeutics. [Mammoth Biosciences]
Mammoth Biosciences has raised $45 million in an oversubscribed Series B financing with the goal of expanding beyond CRISPR-based disease detection—including a collaboration targeting 2019-nCoV coronavirus—towards offerings that apply the company’s platform to gene editing and next-generation therapeutics . . .
